News|Videos|November 13, 2023
Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: Results from MARIPOSA
Expert insight into results from MARIPOSA, a study of frontline amivantamab plus lazertinib in advanced non–small cell lung cancer, and the potential for this regimen’s use in real-world practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
4
Dr Wang Highlights ESMO Lung Cancer Data Making an Impact
5